MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2025 International Congress

    Developing a novel Disease-Specific iPSC Model for Studying MSA Pathogenesis

    A. Perez-Soriano, M. Alemany-Ribes, B. Crespo, F. Kohler, B. Fuste, M. Perez-Soriano, D. Cohen, R. Fernandez-Santiago, M. Ezquerra, MJ. Martí, V. Baekelandt, W. Peelaerts, R. Melki, L. Batlle-Morera, . (Barcelona, Spain)

    Objective: This study aims to develop a human iPSC-derived oligodendrocyte (iPSC-OL) model to investigate cell-specific disease mechanisms in MSA. Specifically, we seek to:a)Generate MSA patient-derived…
  • 2025 International Congress

    GT-02287 in Parkinson’s Disease: Interim Data from a Phase 1b Study

    R. Pozzi, T. Ignoni, M. Bosetti, M. Desciscio, A. Evans, V. Fung, A. Lehn, V. Miller, M. Rentería, R. Schwartz, D. Thyagarajan, S. Tisch, J. Taylor, J. Hannestad (Lugano, Switzerland)

    Objective: To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the brain-penetrant glucocerebrosidase (GCase) modulator GT-02287 in people with Parkinson’s disease with and without a…
  • 2025 International Congress

    The Syn-Sleep Study Detection of Cutaneous Phosphorylated Alpha-Synuclein in REM Sleep Behavior Disorder

    T. Levine, B. Bellaire, R. Freeman, C. Gibbons (scottsdale, USA)

    Objective: The goals of this longitudinal, prospective study are 1) to determine rates of P-SYN deposition in RBD and quantify changes in PSYN deposition over…
  • 2025 International Congress

    Amplification Parameters of the Alpha-Synuclein Seed Amplification Assay on CSF Predict the Clinical Subtype of Parkinson’s Disease at 10-Year Follow-Up

    P. Grillo, GM. Riboldi, A. Pisani, UJ. Kang, SM. Fereshtehnejad (Pavia, Italy)

    Objective: To assess the association between the parameters of alpha-synuclein seed amplification assay on CSF (CSF-αSyn-SAA) within 2 years from Parkinson’s disease (PD) onset and…
  • 2025 International Congress

    Neuroprotective Effects of ATP6V0C Overexpression in PFF Model Mice

    Y. Wang, Y. Xia, L. Kou, T. Wang (wuhan, China)

    Objective: Elucidating the role of lysosomal dysfunction due to altered stability and expression levels of V-type proton subunit ATP6V0C in the degradation and propagation of…
  • 2025 International Congress

    Prevalence of Supine Hypertension in Alpha-Synucleinopathies: a Systematic Review and Meta-Analysis

    V. Arca, PR. Lopes, FL. Westphal Filho, F. Mendes Filho, C. Falcão, J. Parmera (São Paulo, Brazil)

    Objective: We aimed to conduct a systematic review and meta-analysis to assess the prevalence of supine hypertension (SH) in α-synucleinopathies. Background: Alpha-synucleinopathies, including Parkinson’s Disease…
  • 2025 International Congress

    Analysis of the Association between SNCA Polymorphisms and the Risk of Multiple System Atrophy

    N. Abramycheva, M. Andreev, L. Karan, I. Minaev, A. Protopopova, A. Protsenko, E. Fedotova, S. Illaroshkin (Moscow, Russian Federation)

    Objective: To assess the impact of twenty-one single nucleotide polymorphisms (SNPs) located in different regulatory regions of the SNCA gene on the risk of developing…
  • 2025 International Congress

    A Phase 2 Study of Risvodetinib in Untreated Parkinson’s Disease

    M. Werner, C. Meyer, E. Mancino, C. Klint, J. Pellecchia, A. Mcgarry, K. Kieburtz, C. Olanow (Atlanta, USA)

    Objective: Risvodetinib was evaluated in a randomized, double-blind, placebo controlled Phase 2 trial at three doses to determine the safety and tolerability in patients with…
  • 2025 International Congress

    Novel Insights into the Association Between Parkinson’s Disease and Constipation: Role of SHMT2 as a Promising Biomarker

    JH. Su, EX. Tao (Shenzhen, China)

    Objective: This study aims to  analyze the shared molecular pathways between Parkinson’s disease (PD) and constipation through integrative bioinformatics methodologies and further validate candidate biomarkers…
  • 2025 International Congress

    Novel Usage of Alpha Synuclein as a Biomarker for Screening Parkinson’s disease at Komfo Anokye Teaching Hospital in Ghana

    YAW. Osei, SF. Sarfo, FAY. Yeboah Agyemang (Kumasi, Ghana)

    Objective: This study aimed to assess the use of alpha-synuclein as a biomarker for PD screening and investigate its correlation with disease severity. Background: The…
  • 1
  • 2
  • 3
  • …
  • 60
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley